Soleus Capital Management’s Larimar Therapeutics LRMR Stock Holding History

Soleus Capital Management’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$574K	Sell	188,102 -878,858	-82%	-$3.49M	0.02%	92
2026 Q1	$4.8M	Buy	+1,066,960	New	+$4.26M	0.19%	66
2020 Q4	–	Sell	-76,184	Closed	-$1.16M	–	74
2020 Q3	$1.16M	Buy	76,184 +45,014	+144%	+$570K	0.61%	40
2020 Q2	$400K	Sell	31,170 -81,197	-72%	-$946K	0.23%	58
2020 Q1	$1.04M	Buy	112,367 +45,370	+68%	+$596K	1.21%	23
2019 Q4	$892K	Buy	+66,997	New	+$640K	0.86%	30

Other funds holding LRMR

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Defilade Capital Management Emeryville, California $747M AUM

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Soleus Capital Management's LRMR Position: Q2 2026 in Review

Soleus Capital Management reduced its Larimar Therapeutics (LRMR) stake by 82% in Q2 2026, selling an estimated $3.49M and leaving 188,102 shares worth $574K. The position accounts for 0.02% of the portfolio, ranked #92.

Soleus Capital Management first reported a position in LRMR in Q4 2019 and has held it in 6 quarters since. The position peaked at $4.8M in Q1 2026. 163 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

Soleus Capital Management held 188,102 shares of Larimar Therapeutics worth $574K as of Q2 2026.
Soleus Capital Management sold 878,858 Larimar Therapeutics shares in Q2 2026, an estimated $3.49M.
Larimar Therapeutics made up 0.02% of Soleus Capital Management's portfolio in Q2 2026, its #92 holding.
Soleus Capital Management first reported a position in Larimar Therapeutics in Q4 2019 and has held it in 6 quarters since.
Soleus Capital Management's Larimar Therapeutics position peaked at $4.8M in Q1 2026.
163 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on Soleus Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.